UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| 1 |
Linde
LIN
|
$940M |
| 2 |
Abbott
ABT
|
$911M |
| 3 |
Amgen
AMGN
|
$800M |
| 4 |
Pinduoduo
PDD
|
$336M |
| 5 |
Advanced Micro Devices
AMD
|
$289M |
Top Sells
| 1 |
Ametek
AME
|
$485M |
| 2 |
Microsoft
MSFT
|
$301M |
| 3 |
Amazon
AMZN
|
$236M |
| 4 |
VMW
VMware, Inc
VMW
|
$205M |
| 5 |
TSMC
TSM
|
$143M |
Sector Composition
| 1 | Technology | 28.1% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.1% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALX
2501
Alexander's
ALX
$1.2B
| $204K | ﹤0.01% |
+1,053
| New | +$204K |
|
2502
SmartRent
SMRT
$275M
| $203K | ﹤0.01% |
79,431
-23,639
| -23% | -$60.3K |
|
2503
Fate Therapeutics
FATE
$116M
| $202K | ﹤0.01% |
35,408
-42,743
| -55% | -$244K |
|
2504
Forestar Group
FOR
$1.46B
| $201K | ﹤0.01% |
+12,919
| New | +$201K |
|
2505
Blue Bird Corp
BLBD
$1.87B
| $201K | ﹤0.01% |
+9,828
| New | +$201K |
|
|
FLIC
2506
DELISTED
First of Long Island Corp
FLIC
| $198K | ﹤0.01% |
14,662
+3,375
| +30% | +$45.6K |
|
2507
Purple Innovation
PRPL
$122M
| $196K | ﹤0.01% |
74,245
+13,859
| +23% | +$36.6K |
|
2508
NextDecade
NEXT
$2.8B
| $195K | ﹤0.01% |
39,200
| – | – |
|
2509
Douglas Elliman
DOUG
$257M
| $194K | ﹤0.01% |
65,423
| – | – |
|
2510
Oil States International
OIS
$334M
| $191K | ﹤0.01% |
+22,900
| New | +$191K |
|
2511
Adicet Bio
ACET
$60M
| $186K | ﹤0.01% |
+32,279
| New | +$186K |
|
2512
Inogen
INGN
$219M
| $185K | ﹤0.01% |
14,798
| – | – |
|
2513
Old Second Bancorp
OSBC
$970M
| $184K | ﹤0.01% |
13,076
-5,406
| -29% | -$76K |
|
2514
Hagerty
HGTY
$1.17B
| $182K | ﹤0.01% |
20,855
| – | – |
|
2515
Farmers National Banc Corp
FMNB
$567M
| $181K | ﹤0.01% |
+14,300
| New | +$181K |
|
2516
Seer Inc
SEER
$118M
| $181K | ﹤0.01% |
46,818
| – | – |
|
|
CANO
2517
DELISTED
Cano Health, Inc.
CANO
| $180K | ﹤0.01% |
1,977
| – | – |
|
2518
TaskUs
TASK
$1.63B
| $178K | ﹤0.01% |
12,351
-5,182
| -30% | -$74.8K |
|
2519
Esperion Therapeutics
ESPR
$540M
| $177K | ﹤0.01% |
111,482
+39,787
| +55% | +$63.3K |
|
2520
4D Molecular Therapeutics
FDMT
$340M
| $174K | ﹤0.01% |
+10,149
| New | +$174K |
|
2521
Interface
TILE
$1.64B
| $174K | ﹤0.01% |
21,404
-30,815
| -59% | -$250K |
|
2522
Tiptree Inc
TIPT
$849M
| $173K | ﹤0.01% |
+11,900
| New | +$173K |
|
2523
EverQuote
EVER
$860M
| $172K | ﹤0.01% |
+12,356
| New | +$172K |
|
2524
Caribou Biosciences
CRBU
$174M
| $170K | ﹤0.01% |
32,062
-29,300
| -48% | -$156K |
|
2525
Latham Group
SWIM
$960M
| $167K | ﹤0.01% |
58,540
| – | – |
|